Myocardial regeneration in ischemic cardiomyopathy

缺血性心肌病的心肌再生

基本信息

  • 批准号:
    7217448
  • 负责人:
  • 金额:
    $ 36.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-04-15 至 2010-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Acute myocardial infarction (Ml) remains a leading cause of morbidity and mortality. Novel therapeutic strategies involving autologous cell transplantation are being studied, and recently, elegant studies have shown significant regeneration of myocardial tissue by transplantation of autologous stem cells during the peri-infarct period (days following Ml). We have recently shown that the stem cell homing molecule stromal-cell derived factor-1 (SDF-1) is transiently expressed following Ml, and that re-establishment of SDF-1 expression in myocardial tissue months after Ml via the delivery of cells engineered to express SDF-1 is sufficient to induce stem cell homing of hematopoietic stem cells (HSC), vasculogenesis and recovery of myocardial function without the generation of new cardiac myocytes (Lancet 362:697-703, 2003). These observations have led us to hypothesize that a viable strategy for myocardial regeneration in acute Ml and ischemic cardiomyopathy is the overexpression or re-establishment of signaling for stem cell homing to myocardial tissue. Mesenchymal stem cells (MSCs) do home to injured myocardium within days of an Ml and are believed to be more likely to differentiate into cardiac myocytes than HSCs, but they do not express CXCR4. Since MSCs have been shown to mobilize in experimental models of bone marrow injury, and MSC do home to injured myocardium in the peri-infarct period other homing and mobilization factors must be present. We hypothesize that in order to optimize recovery of myocardial function following Ml or in patients with congestive heart failure we need to reestablish both HSC and MSC homing. The overall objectives of this proposal are to test strategies for expressing stem cell homing factors for myocardial regeneration in a model of ischemic cardiomyopathy (Aim 1), identify molecular triggers that lead to homing of bone marrow derived MSCs (Aim 2), and determine if engineering expression of CXCR4 in MSCs leads to homing in response to SDF-1 and a cell survival advantage in vivo (Aim 3).
描述(由申请人提供):急性心肌梗死(Ml)仍然是发病率和死亡率的主要原因。涉及自体细胞移植的新治疗策略正在研究中,最近,一些优雅的研究表明,在梗死周围(Ml后几天),自体干细胞移植可显著再生心肌组织。我们最近的研究表明,干细胞归巢分子基质细胞衍生因子-1 (SDF-1)在Ml后会短暂表达,并且在Ml后几个月,通过传递表达SDF-1的工程化细胞,在心肌组织中重新建立SDF-1的表达,足以诱导造血干细胞(HSC)的干细胞归巢、血管生成和心肌功能的恢复,而无需产生新的心肌细胞(Lancet 362:697- 703,2003)。这些观察结果使我们假设急性Ml和缺血性心肌病心肌再生的可行策略是干细胞归巢到心肌组织的信号的过表达或重建。间充质干细胞(MSCs)在Ml发生后的数天内能够修复受损的心肌,并且被认为比造血干细胞更容易分化为心肌细胞,但它们不表达CXCR4。由于MSCs在骨髓损伤的实验模型中已被证明具有动员作用,并且MSC在梗死周围期对受损心肌具有归巢作用,因此必须存在其他归巢和动员因素。我们假设,为了优化心肌梗死后或充血性心力衰竭患者心肌功能的恢复,我们需要重建HSC和MSC归巢。本提案的总体目标是测试在缺血性心肌病模型中表达干细胞归巢因子用于心肌再生的策略(目的1),确定导致骨髓来源的MSCs归巢的分子触发器(目的2),并确定MSCs中CXCR4的工程表达是否导致SDF-1响应的归巢和细胞在体内的生存优势(目的3)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARC S PENN其他文献

MARC S PENN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARC S PENN', 18)}}的其他基金

Phase II Trial Evaluating the Safety and Efficacy of an Allogeneic Stem Cell for
评估同种异体干细胞的安全性和功效的 II 期试验
  • 批准号:
    8591725
  • 财政年份:
    2013
  • 资助金额:
    $ 36.27万
  • 项目类别:
Phase II Trial Evaluating the Safety and Efficacy of an Allogeneic Stem Cell for
评估同种异体干细胞的安全性和功效的 II 期试验
  • 批准号:
    8720903
  • 财政年份:
    2013
  • 资助金额:
    $ 36.27万
  • 项目类别:
Phase II Trial Evaluating the Safety and Efficacy of an Allogeneic Stem Cell for
评估同种异体干细胞的安全性和功效的 II 期试验
  • 批准号:
    8998972
  • 财政年份:
    2013
  • 资助金额:
    $ 36.27万
  • 项目类别:
CORE---Animal Model
核心---动物模型
  • 批准号:
    7665468
  • 财政年份:
    2008
  • 资助金额:
    $ 36.27万
  • 项目类别:
Myocardial regeneration in ischemic cardiomyopathy
缺血性心肌病的心肌再生
  • 批准号:
    7052090
  • 财政年份:
    2005
  • 资助金额:
    $ 36.27万
  • 项目类别:
Myocardial regeneration in ischemic cardiomyopathy
缺血性心肌病的心肌再生
  • 批准号:
    7598916
  • 财政年份:
    2005
  • 资助金额:
    $ 36.27万
  • 项目类别:
Myocardial regeneration in ischemic cardiomyopathy
缺血性心肌病的心肌再生
  • 批准号:
    6918451
  • 财政年份:
    2005
  • 资助金额:
    $ 36.27万
  • 项目类别:
Myocardial regeneration in ischemic cardiomyopathy
缺血性心肌病的心肌再生
  • 批准号:
    7388177
  • 财政年份:
    2005
  • 资助金额:
    $ 36.27万
  • 项目类别:
CORE---Animal Model
核心---动物模型
  • 批准号:
    6853433
  • 财政年份:
    2004
  • 资助金额:
    $ 36.27万
  • 项目类别:
MECHANISM OF TISSUE FACTOR ACTIVATION BY OXIDANT STRESS
氧化应激激活组织因子的机制
  • 批准号:
    6030449
  • 财政年份:
    1999
  • 资助金额:
    $ 36.27万
  • 项目类别:

相似海外基金

Non-invasive coronary thrombus imaging to define the cause of acute myocardial infarction
无创冠状动脉血栓显像可明确急性心肌梗塞的病因
  • 批准号:
    MR/Y009770/1
  • 财政年份:
    2023
  • 资助金额:
    $ 36.27万
  • 项目类别:
    Fellowship
Impact of COVID-19 pandemic on pathophysiology of acute myocardial infarction and emergency cardiovascular care system
COVID-19大流行对急性心肌梗死病理生理学和心血管急诊系统的影响
  • 批准号:
    23K15160
  • 财政年份:
    2023
  • 资助金额:
    $ 36.27万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Extreme Heat and Acute Myocardial Infarction: Effect Modifications by Sex, Medical History, and Air Pollution
酷热和急性心肌梗塞:性别、病史和空气污染的影响
  • 批准号:
    10709134
  • 财政年份:
    2023
  • 资助金额:
    $ 36.27万
  • 项目类别:
Development of a multi-RNA signature in blood towards a rapid diagnostic test to robustly distinguish patients with acute myocardial infarction
开发血液中的多 RNA 特征以进行快速诊断测试,以强有力地区分急性心肌梗死患者
  • 批准号:
    10603548
  • 财政年份:
    2023
  • 资助金额:
    $ 36.27万
  • 项目类别:
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
  • 批准号:
    10576349
  • 财政年份:
    2022
  • 资助金额:
    $ 36.27万
  • 项目类别:
Establishment of the emergency transport decision making program for patients with acute myocardial infarction using artificial intelligence (AI)
利用人工智能(AI)建立急性心肌梗死患者紧急转运决策方案
  • 批准号:
    22K09185
  • 财政年份:
    2022
  • 资助金额:
    $ 36.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Developing Federated Learning Strategies for Disease Surveillance Using Cross-Jurisdiction Electronic Medical Records without Data Sharing: With Applications to Acute Myocardial Infarction, Hypertension, and Sepsis Detection
使用跨辖区电子病历(无需数据共享)开发疾病监测联合学习策略:在急性心肌梗塞、高血压和脓毒症检测中的应用
  • 批准号:
    468573
  • 财政年份:
    2022
  • 资助金额:
    $ 36.27万
  • 项目类别:
    Operating Grants
Evaluation of effect of intracoronary supersaturated oxygen therapy on inhibition of no reflow phenomenon in acute myocardial infarction
冠状动脉内过饱和氧治疗抑制急性心肌梗死无复流现象的效果评价
  • 批准号:
    22K08135
  • 财政年份:
    2022
  • 资助金额:
    $ 36.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
  • 批准号:
    10339915
  • 财政年份:
    2022
  • 资助金额:
    $ 36.27万
  • 项目类别:
The Personalising Acute Myocardial Infarction Care to improve Outcomes (PAMICO Project)
个性化急性心肌梗死护理以改善结果(PAMICO 项目)
  • 批准号:
    nhmrc : 2005797
  • 财政年份:
    2021
  • 资助金额:
    $ 36.27万
  • 项目类别:
    Partnership Projects
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了